

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 15280-2912

Assistant Commissioner for Patents
Washington, D.C. 20231

On

3/12/99

TOWNSEND and TOWNSEND and CREW LLP

By

Jennifer K. Hardi

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GOZES et al.

Application No.: 09/187,330

Filed: 11/6/98

For: ACTIVITY DEPENDENT
NEUTROTROPHIC FACTOR III (ADNF
III)

Examiner:

Art Unit: 1643

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Search/Examination report cited in conjunction with the PCT parent application, international application number PCT/US98/02485. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Annette S. Parent
Reg. No. 42058

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
ASP:pb

4582

FORM PTO-1449 (Modified)		Attorney Docket No.: 15280-2912		Application No.: 09/187,330	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Gozes et al.			
		Filing Date: 11/6/98		Group: 443 163/	
Reference Designation				Page 1	
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
<i>mr</i> AA	5,767,240	06/16/98	Brenneman et al.	530	350
FOREIGN PATENT DOCUMENTS					
	Document No.	Date	Country	Class	Translation (Yes/No)
<i>mr</i> AB	WO 92/18140	10/29/92	WIPO		
AC	WO 96/11948	04/25/96	WIPO		
AD	WO 98/35042	08/13/98	WIPO		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)					
AE	Bassan, M. et al. "VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein." <i>Regulatory Peptides</i> , Vol. 71, No. 2, August 15, 1997.				
AF	Bassan, M. et al. "Complete Sequence of a Novel Protein Containing a Femtomolar-Activity-Dependent Neuroprotective Peptide." <i>Journal of Neurochemistry</i> , Vol 72, pp. 1283-1293 (1999)				
AG	Beni-Adani, L. et al. "Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury." Society for Neuroscience, 28 th Annual Meeting, Los Angeles, CA, November 7-12, 1998. <i>Abstracts</i> , Vol. 23, Part 1, p. 1043 (1998).				
AH	Brenneman, D.C. and Gozes, I. "A Femtomolar-Acting Neuroprotective Peptide." <i>Journal of Clinical Investigation</i> , Vol. 97, pp. 229-2307 (1996)				
AI	Brenneman, D.E. et al. "Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2250 (1997).				
AJ	Brenneman, D.E. et al. "Activity-Dependent neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides." <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 285, pp. 619-627 (1998)				
AK	Davidson, A. et al. "Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2250 (1997).				
AL	Dibbern, D.A., Jr. et al. "Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor." <i>Journal of Clinical Investigation</i> , Vol. 99, pp. 28377-2841 (1997)				
AM	Giladi, E. "Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides." <i>Neuroscience Letters</i> , Supplement 48 S1-S60, P. S19 (1997).				
AN	Glazner, G.W. et al. "A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death." Society for Neuroscience, 27 th Annual Meeting, New Orleans, LA, October 25-30, 1997. <i>Abstracts</i> , Vol. 23, Part 2, p. 2249 (1997).				
AO	Gozes, I. et al. "Stearyl-Norleucine-Vasoactive intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment." <i>Endocrinology</i> , Vol. 134, pp. 2125 (1994).				
AP	Gozes, I. et al. "Supractive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors." <i>Journal of Pharmacology and Experimental Therapeutics</i> , Vol. 273, pp. 161-167 (1995).				
AQ	Gozes, I. et al. "Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide." <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 427-432 (1996).				
✓ AR	Gozes, I. and Brenneman, D.E. "Activity-Dependent Neurotrophic Factor (ADNF)." <i>Journal of Molecular Neuroscience</i> , Vol. 7, pp. 235-244 (1996).				
EXAMINER		DATE CONSIDERED			
<i>mrallen</i>		7/12/00			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

